manufacturers; and other important factors discussed under the caption "Risk Factors†in our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025, June 30, 2025, and September 30, 2025 as any such factors may be updated from time to time in our other filings with the U.S. Securities and Exchange Commission (SEC), which are accessible on the SEC's website at [www.sec.gov] and the Investors page of our website unde ...

Core Viewpoint - Precision BioSciences, Inc. is advancing its gene editing therapies through its proprietary ARCUS® platform, focusing on unmet medical needs and outlining strategic priorities for 2026, with significant progress in its lead programs and a strong financial position to support upcoming milestones [1][2]. Clinical Programs - The PBGENE-HBV program is in a Phase 1/2a ELIMINATE-B trial aimed at curing chronic Hepatitis B by eliminating cccDNA, with positive dose-dependent effects and antiviral activity reported [3][4]. - Safety data from the PBGENE-HBV trial indicated no dose-limiting toxicities at doses up to 0.8 mg/kg, with manageable adverse events observed [4][5]. - Additional dosing cohorts are being explored to optimize the therapeutic index, with 12 participants having completed at least one dose administration [5][6]. - The PBGENE-DMD program is set to begin its Phase 1/2 FUNCTION-DMD trial in late Q1 or early Q2 2026, targeting DMD patients with specific mutations, with initial data expected by the end of 2026 [8][10]. Partnered Programs - ECUR-506, developed by iECURE, is being evaluated for neonatal onset OTC deficiency and has received FDA RMAT designation, with data expected in the first half of 2026 [11]. - The azer-cel CAR T treatment is being developed by Imugene for diffuse large B-cell lymphoma, with Precision receiving an $8 million milestone payment due to progress [12]. - Additional milestone payments are anticipated from TG Therapeutics for azer-cel's ongoing Phase 1 trial in progressive multiple sclerosis [13]. Financial Position - Precision BioSciences expects to report approximately $137 million in cash and equivalents as of December 31, 2025, with a cash runway projected through 2028 to support ongoing clinical programs [14].

Core Insights - Precision BioSciences, Inc. is a clinical stage gene editing company focused on developing in vivo gene editing therapies for diseases with high unmet needs [1] Company Announcement - The company announced it will deliver an oral presentation at the Hep-DART 2025 meeting scheduled for December 7–11, 2025, in Honolulu, Hawaii [1] - The presentation will showcase data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV [1]

Core Viewpoint - Precision BioSciences, Inc. has announced an underwritten offering to sell 10,815,000 shares of its common stock along with warrants to purchase up to 5,407,500 additional shares at a combined price of $6.14 [1] Company Summary - The company is a clinical stage gene editing firm utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies targeting diseases with high unmet needs [1] - The offering includes both common stock and accompanying warrants, indicating a strategy to raise capital for further development [1]

Core Insights - Precision BioSciences, Inc. is a clinical stage gene editing company focused on developing in vivo gene editing therapies for diseases with high unmet needs [1] Group 1 - The company announced a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 [1] - The presentation will include data from the ongoing ELIMINATE-B Phase 1 study [1] - The study evaluates PBGENE-HBV, which is described as a first-in-class in vivo gene editing therapy [1]

Core Insights - Precision BioSciences, Inc. reported financial results for Q3 2025, highlighting significant advancements in its gene editing pipeline and promising Phase 1 safety and efficacy data for its product PBG [1] Financial Performance - The company announced its financial results for the third quarter ended September 30, 2025, indicating progress in its operations [1] Business Update - Precision BioSciences emphasized strong progress in its gene editing pipeline throughout the third quarter, showcasing the effectiveness of its proprietary ARCUS® platform [1]

Core Insights - Precision BioSciences, Inc. is a clinical stage gene editing company focused on developing in vivo gene editing therapies for diseases with high unmet needs [1] - The company will publish its financial results for the third quarter of 2025 and provide a business update on November 3, 2025 [1] Company Overview - Precision BioSciences utilizes its proprietary ARCUS® platform for gene editing [1] - The company is dedicated to improving life through innovative gene editing solutions [1]

Core Insights - Precision BioSciences, Inc. has been selected for a late-breaking oral presentation at the Liver Meeting® 2025, highlighting its innovative gene editing capabilities [1] Company Summary - The company specializes in gene editing using its proprietary ARCUS® platform, focusing on developing in vivo gene editing therapies for diseases with high unmet medical needs [1] - The presentation will showcase new data from the PBGENE-HBV program, specifically from the first two cohorts of the Phase 1 ELIMINATE-B Trial [1]

Core Insights - Precision BioSciences, Inc. is a clinical stage gene editing company focused on developing in vivo gene editing therapies for diseases with high unmet needs [1] - The company announced the publication of a peer-reviewed manuscript in the journal Nucleic Acids Research, showcasing the efficiency of its proprietary ARCUS® platform [1] - The publication highlights the capability of the engineered homing endonuclease ARCUS for high-efficiency homology-directed insertion into the genome [1] Company Summary - Precision BioSciences utilizes its novel ARCUS® platform for gene editing, targeting diseases that currently lack effective treatments [1] - The recent publication serves to validate the technology and its potential applications in gene therapy [1] - The focus on in vivo therapies indicates a strategic direction towards addressing complex genetic disorders [1]

Core Insights - Precision BioSciences, Inc. has activated its first U.S. clinical trial site for PBGENE-HBV as part of the ELIMINATE-B Phase 1 clinical trial [1] - The clinical trial site is located at Massachusetts General Hospital in Boston, Massachusetts, and is now actively recruiting patients [1] Company Overview - Precision BioSciences is a clinical stage gene editing company that utilizes its proprietary ARCUS® platform [1] - The company focuses on developing in vivo gene editing therapies for diseases with high unmet medical needs [1]